Verastem Oncology recently launched an awareness campaign focused on low-grade serous ovarian cancer (LGSOC). As part of the Let’s Talk About LGSOC initiative, the development-stage biopharma is ...

The investigational combination of avutometinib (a dual RAF/MEK inhibitor) and defactinib (a FAK inhibitor) achieved very high response rates in heavily pretreated patients with recurrent low-grade ...

Show More From the Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX. Development of a binary grading system for serous ...

High-Dose Chemotherapy and Autologous Peripheral-Blood Stem-Cell Transplantation for Relapsed Metastatic Germ Cell Tumors: The Indiana University Experience Eligibility criteria for patients from our ...

One type of ovarian cancer looks likely to be a new indication for the MEK inhibitor trametinib (Mekinist), which is already approved in the US for use in melanoma, non–small cell lung cancer, and ...

BOSTON--(BUSINESS WIRE)--Verastem Oncology, (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with cancer, today announced results of the first-ever LGSOC ...

Jessica BeCraft, 33, was diagnosed with stage 3c low-grade serous ovarian cancer (LGSOC) in 2018. BeCraft quickly discovered that there was a dearth of information about this rare subtype of the ...

Overall, 23% of 48 patients had partial responses, increasing to 26% in those who had baseline and confirmatory CT scans. Almost 80% obtained clinical benefit. Median duration of response was 19.1 ...

BOSTON--(BUSINESS WIRE)--Verastem Oncology, (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with cancer, today announced that an abstract highlighting ...

Verastem Oncology Announces Publication of the Primary Results from the Phase 2 RAMP 201 Trial of Avutometinib in Combination with Defactinib in Patients with Recurrent Low-Grade Serous Ovarian Cancer ...